Cleopatra-PD: Clinical efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease

被引：0

作者：

Poewe, W. H. ^{[1
]}

Rascol, O. ^{[2
]}

Quinn, N. ^{[3
]}

Tolosa, E. ^{[4
]}

Oertel, W. H. ^{[5
]}

Martignoni, E. ^{[6
]}

Rupp, M. ^{[7
]}

Boroojerdi, B. ^{[7
]}

机构：

[1] Innsbruck Med Univ, Dept Neurol, Innsbruck, Austria

[2] Ctr Hosp Univ, Serv Pharmacol Clin, Toulouse, France

[3] UCL, Inst Neurol, London, England

[4] Hosp Clin Univ, Serv Neurol, Barcelona, Spain

[5] Univ Marburg, Dept Neurol, Marburg, Germany

[6] Univ Piemonte Orientale, Novara, Italy

[7] Schwarz Pharma, Monheim, Germany

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2007年 / 14卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：11 / 11

页数：1

共 50 条

[41] The efficacy of pramipexole in the treatment of Parkinson's disease
Lieberman, A
Minagar, A
Pinter, MM
REVIEWS IN CONTEMPORARY PHARMACOTHERAPY, 2001, 12 (1-2): : 59 - 86
[42] Efficacy and safety of pramipexole extended-release for advanced Parkinson's disease
Rascol, O.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 : 15 - 15
[43] The long-term safety and efficacy of pramipexole in advanced Parkinson's disease
Weiner, WJ
Factor, SA
Jankovic, J
Hauser, RA
Tetrud, JW
Waters, CH
Shulman, LM
Glassman, PM
Beck, B
Paume, D
Doyle, C
NEUROLOGY, 1999, 52 (06) : A261 - A262
[44] Rotigotine transdermal patch in combination therapy for Parkinson's disease - observations in routine clinical practice
Ceballos-Baumann, Andres
Haeck, Hermann-Josef
CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (10) : 1899 - 1905
[45] Safety and tolerability of transdermal rotigotine in early stage Parkinson's disease
Watts, Ray L.
Patton, James M.
Poewe, Werner
Boroojerdi, Babak
ANNALS OF NEUROLOGY, 2006, 60 : S82 - S82
[46] Treatment of patients with early and advanced Parkinson's disease with transdermal rotigotine: age relationship to safety and tolerability
Oertel, W.
LeWitt, P.
Grieger, F.
Bauer, L.
Boroojerdi, B.
EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 532 - 532
[47] Safety and efficacy of transdermal rotigotine for the treatment of fatigue and quality of life (QOL) in patients with Parkinson's disease
Abe, K.
Kitamura, S.
Yokoa, I.
Ogura, J.
Fjita, M.
Yoshikawa, H.
MOVEMENT DISORDERS, 2015, 30 : S148 - S149
[48] Rotigotine: A novel dopamine agonist for the transdermal treatment of Parkinson's disease
Zareba, G
DRUGS OF TODAY, 2006, 42 (01): : 21 - 28
[49] Treatment of patients with early and advanced Parkinson's disease with transdermal rotigotine: safety and tolerability in elderly patients
Oertel, W.
LeWitt, P.
Watts, R.
Grieger, F.
Bauer, L.
Boroojerdi, B.
PARKINSONISM & RELATED DISORDERS, 2009, 15 : S129 - S129
[50] Safety and tolerability of rotigotine transdermal system in patients over 70 years with advanced Parkinson's disease
Capecci, M.
Andrenelli, E.
Sordoni, E.
Monsu, A. M.
Di Biagio, L.
Ceravolo, M. G.
MOVEMENT DISORDERS, 2014, 29 : S136 - S136

← 1 2 3 4 5 →